"Unser am 01.01.2016 gegründetes Zentrum ist aus der langjährig bekannten Gemeinschaftspraxis Driesener Straße hervorgegangen und umfasst 3 Standorte. Wir verstehen uns als eine allgemeinmedizinisch-internistische Gesamtpraxis mit hausärztlicher Versorgung sowie infektiologischen und hepatologischen Schwerpunkten. Wir fühlen uns seit 1992 zuständig für die gesundheitliche Versorgung unseres „Kiezes“ im Prenzlauer Berg ebenso wie für alle, die uns mit ihren gesundheitlichen Problemen aufsuchen, unabhängig von Geschlecht, Alter, Religion, Weltanschauung, Herkunft, Aufenthaltsstatus oder sexueller Orientierung."

During the past decade, Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" #1 sponsor was "Gilead Sciences" with 5 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Kirby Institute" with 2 trials sponsored, "Eiger BioPharmaceuticals" with 1 trials sponsored and "Hologic, Inc." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" are "HIV-1 Infection" (3 trials), "Hepatitis C, Chronic" (3 trials), "HIV-1-infection" (2 trials), "Hepatitis B, Chronic" (2 trials) and "Acute Respiratory Infection" (1 trials). Many other conditions were trialed in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" in a lesser frequency.

Most popular intervention types in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" are "Drug" (12 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "FTC/RPV/TAF" (2 trials), "FTC/RPV/TAF Placebo" (2 trials), "JNJ-56136379" (2 trials) and "JNJ-73763989" (2 trials). Other intervention names were less common.

The vast majority of trials in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH" are 16 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".